0000000000292433

AUTHOR

Ron H.n. Van Schaik

showing 2 related works from this author

The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Pro…

2017

Abstract Background The androgen receptor splice variant 7 (AR-V7) is associated with resistance to hormonal therapy in castration-resistant prostate cancer (CRPC). Due to limitations of the methods available for AR-V7 analysis, the identification of a reliable detection method may facilitate the use of this biomarker in clinical practice. Objective To confirm AR-V7 as a predictor of resistance to hormonal therapy and develop a new approach to assess AR-V7 by highly sensitive digital droplet polymerase chain reaction (ddPCR) in plasma-derived exosomal RNA. Design, setting, and participants Plasma samples were collected from 36 CRPC patients before they began second-line hormonal treatment. …

Oncology0301 basic medicineMaleResistanceExosomeschemistry.chemical_compoundProstate cancer0302 clinical medicineProtein IsoformsNeoplasm MetastasisReceptorAged 80 and overProstate cancerMiddle AgedProstatic Neoplasms Castration-ResistantReceptors Androgen030220 oncology & carcinogenesisBenzamidesAdenocarcinomaBiomarker (medicine)Hormonal therapyAR-V7; Digital droplet PCR; Exosomes; Hormonal therapy; Pharmacogenetics; Prostate cancer; Resistance; UrologyAndrostenesHormonal therapymedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classUrologyCastration resistantAdenocarcinomaDisease-Free Survival03 medical and health sciencesSDG 3 - Good Health and Well-beingInternal medicineNitrilesPhenylthiohydantoinmedicineEnzalutamideHumansAgedDigital droplet PCRPlasma derivedbusiness.industryRNAAndrogen Receptor Splice Variant 7medicine.diseaseAndrogenEndocrinology030104 developmental biologychemistryPharmacogeneticsDrug Resistance NeoplasmCancer cellCancer researchRNAAR-V7businessPharmacogenetics
researchProduct

Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin

2016

Metformin is the first-line antidiabetic drug with over 100 million users worldwide, yet its mechanism of action remains unclear(1). Here the Metformin Genetics (MetGen) Consortium reports a three-stage genome-wide association study (GWAS), consisting of 13,123 participants of different ancestries. The C allele of rs8192675 in the intron of SLC2A2, which encodes the facilitated glucose transporter GLUT2, was associated with a 0.17% (P = 6.6 x 10(-14)) greater metformin-induced reduction in hemoglobin A1c (HbA1c) in 10,577 participants of European ancestry. rs8192675 was the top cis expression quantitative trait locus (cis-eQTL) for SLC2A2 in 1,226 human liver samples, suggesting a key role …

Blood Glucose0301 basic medicinemedicine.medical_specialtyendocrine system diseasesGenome-wide association studyType 2 diabetesPolymorphism Single NucleotideWhite PeopleBody Mass Index03 medical and health sciencesQuantitative Trait HeritableInternal medicineDiabetes mellitusGeneticsmedicineHumansHypoglycemic AgentsAlleleGlycemicGlucose Transporter Type 2Glycated HemoglobinbiologyGlucose transporternutritional and metabolic diseasesmedicine.diseaseMetformin3. Good healthMetformin030104 developmental biologyEndocrinologyDiabetes Mellitus Type 2biology.proteinGLUT2Genome-Wide Association Studymedicine.drug
researchProduct